|
FY2014
12 months to Dec 31, 2014
|
|
|---|---|
| Operating activities | |
| Net loss | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |
| Depreciation and amortization | |
| Amortization of lease incentive | |
| Stock-based compensation | |
| Series B warrant mark-to-market expense | |
| Series B Warrant | |
| Total series B warrant mark-to-market expense | |
| Other | |
| Amortization of deferred debt issuance costs | |
| Amortization of debt discount | |
| Amortization of premium on marketable securities | |
| Changes in operating assets and liabilities: | |
| Prepaid expenses and other assets | |
| Accounts payable | |
| Clinical trial accrual | |
| Accrued expenses | |
| Deferred rent | |
| Net cash used in operating activities | |
| Investing activities | |
| Purchases of property and equipment | |
| Purchase of short-term investments | |
| Net cash used in investing activities | |
| Financing activities | |
| Proceeds from issuance of note payable, net of issuance costs | |
| Payment of debt issuance costs for long-term debt | |
| Proceeds from exercise of stock options | |
| Proceeds from exercise of warrants | |
| Proceeds from issuance of preferred stock, net of issuance costs | |
| Series C Preferred Stock | |
| Series D Preferred Stock | |
| Proceeds from issuance of common stock, net of issuance costs | |
| Principal payments on capital lease | |
| Restricted cash | |
| Net cash provided by financing activities | |
| Net increase (decrease) in cash and cash equivalents | |
| Cash and cash equivalents at beginning of period | |
| Cash and cash equivalents at end of period | |
| Supplemental disclosures of cash flow information | |
| Cash paid for interest | |
| Cash paid for taxes | |
| Non-cash investing and financing activities: | |
| Non-cash additions to property and equipment |
Loading...
